RORγ modulators

US10035790B2 · kind B2 · utility

Assignees

• Exelixis, Inc. · US
• Bristol-Myers Squibb Company · US

Inventors

• Wei Xu · Saginaw, US
• Yong Wang · South San Francisco, US
• Sunghoon Ma · Foster City, US
• Elena S. Koltun · Foster City, US
• Byung Gyu Kim · Daejeon, KR
• Joon Won Jeong · Belmont, US
• T. G. Murali Dhar · Newtown, US
• Lynne Canne Bannen · Lucerne, US

Key dates

• Filing date: Oct 17, 2013
• Grant date: Jul 31, 2018
• Expiry date: Oct 17, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R1, R2, R3, R4, R5, R6, Ra, x, y, L, G, Z, the bond denoted by “q”, the ring system denoted by “A” and the ring system denoted by “B” are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.